Exp Mol Med.
2009 Feb;41(2):61-66. 10.3858/emm.2009.41.2.008.
Improving vaccines by targeting antigens to dendritic cells
- Affiliations
-
- 1The Walter and Eliza Hall Institute of Medical Research, Parkville Victoria 3050, Australia. shortman@wehi.edu.au
- KMID: 1109428
- DOI: http://doi.org/10.3858/emm.2009.41.2.008
Abstract
- A new approach to enhancing the effectiveness of vaccines is to deliver antigens selectively to dendritic cells (DC) in situ, via monoclonal antibodies specific for particular DC surface molecules. This can markedly enhance CTL responses and, via helper T cells, also enhance antibody responses. DC activation agents or adjuvants must also be administered for effective CTL responses, but in some cases good antibody responses can be obtained without adjuvants. Here we review the role of different DC subsets and different DC target molecules in obtaining enhanced immune responses.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Distinct features of dendritic cell-based immunotherapy as cancer vaccines
- Cancer Vaccines Targeting HER2/neu for Early Breast Cancer
- Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
- Vaccine strategies utilizing C-type lectin receptors on dendritic cells in vivo
- Cancer Vaccines
